Federal Circuit Rules Sumitomo’s Expired Drug Patent Appeal as Moot
The U.S. Patent and Trademark Office (USPTO) scored a recent victory, with the Federal Circuit determining that Sumitomo Pharma’s appeal concerning a decision that invalidated all claims of its patent is now moot. The patent, pertaining to a dosage regimen for a schizophrenia drug, expired just prior to the appeals court hearing oral arguments. Sumitomo…